Calmark receives Notice of Allowance regarding patent in China
Calmark Sweden AB (publ) announces today that the Chinese patent office China National Intellectual Property Administration (”CNIPA”) has issued a notice of allowance regarding Calmark's patent application covering the POC system.
Patent application no. 201880011863.5, entitled "Detection of a biomarker in a sample of a flowable substance" covers the entire POC system and the method of detecting a biomarker in e.g. blood. The patent provides protection until 2038. The notice of allowance means that the CNIPA will approve the company's patent application and issue the patent.
Including the new patent, Calmark owns 20 patents and 11 design protections for both the instrument and the test cassette on important markets.
"We continue the systematic patent work and focus on markets where the value of patent protection is the highest," says Camilla Arneving, acting CEO of Calmark. "China invests heavily in intangible assets and the number of patent applications increases year by year. Therefore, it is especially important that our application now is approved."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50
E-post: camilla.arneving@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.